Goldman Sachs Group Inc cut shares of Evolent Health Inc (NYSE:EVH) from a conviction-buy rating to a buy rating in a report released on Tuesday, November 7th, The Fly reports.
Several other equities research analysts have also issued reports on the stock. SunTrust Banks, Inc. reiterated a buy rating and issued a $30.00 price target on shares of Evolent Health in a research note on Friday, November 3rd. Jefferies Group LLC reiterated a buy rating and issued a $28.00 price target on shares of Evolent Health in a research note on Wednesday, September 6th. Cantor Fitzgerald reiterated a buy rating and issued a $30.00 price target on shares of Evolent Health in a research note on Thursday, November 2nd. BidaskClub lowered shares of Evolent Health from a strong-buy rating to a buy rating in a research note on Tuesday, July 25th. Finally, Zacks Investment Research upgraded shares of Evolent Health from a sell rating to a hold rating in a research note on Monday, October 9th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the stock. The company has an average rating of Buy and an average price target of $28.00.
Shares of Evolent Health (NYSE:EVH) opened at $12.05 on Tuesday. Evolent Health has a twelve month low of $10.30 and a twelve month high of $27.50. The company has a current ratio of 3.34, a quick ratio of 3.34 and a debt-to-equity ratio of 0.11.
Several hedge funds have recently made changes to their positions in the stock. ETF Managers Group LLC bought a new stake in Evolent Health in the 2nd quarter valued at about $102,000. BNP Paribas Arbitrage SA boosted its holdings in Evolent Health by 815.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock valued at $120,000 after purchasing an additional 4,232 shares during the period. First Mercantile Trust Co. bought a new stake in Evolent Health in the 2nd quarter valued at about $198,000. Royal Bank of Canada boosted its holdings in Evolent Health by 1,197.8% in the 2nd quarter. Royal Bank of Canada now owns 8,293 shares of the technology company’s stock valued at $210,000 after purchasing an additional 7,654 shares during the period. Finally, SG Americas Securities LLC bought a new stake in Evolent Health in the 3rd quarter valued at about $156,000. 98.53% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This news story was reported by BBNS and is the property of of BBNS. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/evolent-health-inc-evh-lowered-to-buy-at-goldman-sachs-group-inc-the/1764658.html.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with our FREE daily email newsletter.